DaVita Inc. (NYSE:DVA – Get Free Report) has been assigned a consensus recommendation of “Hold” from the six analysts that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and one has issued a buy recommendation on the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $164.50.
Several research analysts have issued reports on DVA shares. Truist Financial dropped their target price on shares of DaVita from $170.00 to $164.00 and set a “hold” rating on the stock in a report on Monday, May 19th. Wall Street Zen upgraded shares of DaVita from a “hold” rating to a “buy” rating in a report on Friday, April 25th.
View Our Latest Stock Report on DaVita
DaVita Trading Up 2.2%
DaVita (NYSE:DVA – Get Free Report) last posted its quarterly earnings results on Monday, May 12th. The company reported $2.00 EPS for the quarter, topping the consensus estimate of $1.75 by $0.25. The company had revenue of $3.22 billion for the quarter, compared to the consensus estimate of $3.22 billion. DaVita had a net margin of 6.63% and a return on equity of 176.11%. The firm’s revenue was up 5.0% compared to the same quarter last year. During the same quarter last year, the firm posted $2.26 EPS. As a group, analysts expect that DaVita will post 10.76 EPS for the current year.
Institutional Investors Weigh In On DaVita
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Wellington Management Group LLP boosted its stake in DaVita by 9.1% during the 4th quarter. Wellington Management Group LLP now owns 2,711 shares of the company’s stock worth $405,000 after purchasing an additional 227 shares during the last quarter. Fifth Third Bancorp boosted its position in shares of DaVita by 5.0% during the 1st quarter. Fifth Third Bancorp now owns 4,274 shares of the company’s stock valued at $654,000 after acquiring an additional 204 shares during the last quarter. Concurrent Investment Advisors LLC acquired a new position in shares of DaVita during the 1st quarter valued at about $223,000. Wealth Enhancement Advisory Services LLC boosted its position in shares of DaVita by 22.5% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 4,351 shares of the company’s stock valued at $666,000 after acquiring an additional 800 shares during the last quarter. Finally, OneDigital Investment Advisors LLC acquired a new position in shares of DaVita during the 1st quarter valued at about $200,000. Institutional investors and hedge funds own 90.12% of the company’s stock.
DaVita Company Profile
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Further Reading
- Five stocks we like better than DaVita
- What Do S&P 500 Stocks Tell Investors About the Market?
- The Market Rally Is Gaining Momentum—Don’t Get Left Behind
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- High-Flying GE Aerospace Drops After Blowout Q2 — What Now?
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate
Receive News & Ratings for DaVita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita and related companies with MarketBeat.com's FREE daily email newsletter.